My5-FU is designed to measure levels of 5-FU, an anti-cancer drug, in the blood of cancer patients.

Under the agreement, INyDIA will also help oncologists to individualize 5-FU dosing to optimize therapeutic efficacy and reduce toxicity for their patients.

INyDIA country manager Santiago Maceira said the company is pleased to provide Saladax’s technology to oncologists in Spain and Portugal to ensure personalized care is provided to their patient populations.